Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

• Positive Phase 3 trial results for the weight-loss pill Foundayo showed it reduced sleep-apnea breathing interruptions by up to an average of 44% after 52 weeks, with plans to seek FDA approval for this new indication by year-end 2026, potentially broadening the drug's commercial opportunity beyond weight loss.
• Strong quarterly financial performance was reported on October 29, 2026, with earnings per share of $7.48 significantly topping the consensus estimate of $5.71, and revenue of $24.40 billion exceeding the consensus estimate of $22.58 billion, reflecting a 38.6% year-over-year revenue increase.
• Recent analyst upgrades have boosted investor confidence, including Jefferies Financial Group raising its price target to $1,700.00 and Morgan Stanley increasing its target to $1,596.00, contributing to a current stock price of $1,413.22 which represents a 4.4% increase in recent trading.
• Expanded digital access to branded obesity drugs Zepbound and Foundayo through new partnerships with Hims & Hers and LifeMD will offer eligible U.S. adults telehealth and prescription fulfillment, potentially widening the company's market reach and patient base.
• Institutional investors continue to show strong conviction in the company, with major holders like BlackRock Inc. and State Street Corp increasing their stakes in the second quarter, and institutional investors and hedge funds collectively owning 82.53% of the company's stock.